S&P 500 7,457.69 -1.01% NASDAQ 25,520.24 -1.40% DOW 52,146.42 -0.77% R2K 2,962.22 -0.42% VIX 18.77 +12.19% US 10Y 4.54 -0.61% DXY 100.75 +0.02% BITCOIN 64,539.67 -0.40%
Next Bullish Trade
Sign in
GRAL

GRAIL, Inc. NMS · GRAL

$72.62 +0.66 (+0.92%)
Neutral · +0.81σ

Price chart

Timeframe
Range
Fundamentals · free Click ▲ earnings markers (daily) for the day's move

Loading…

Latest bar · GRAL

Momentum reads · latest daily bar
Last
$72.62
+0.66 (+0.92%)
Mkt cap
$3.1B
Healthcare
RSI(14)
59.7
neutral
Stochastic %K
74.0
neutral
MFI(14)
61.9
neutral
ADX(14)
27.0
trending

Green means room to run, red means stretched — the reads re-read live as you switch the chart's timeframe. MFI(14) is a volume-weighted money-flow read: above 80 = overbought, below 20 = oversold.

Financial overlay · last 12 quarters

The story behind the price: three years of quarterly results laid over the chart, so you can see whether the stock has been following the business — or running ahead of it.

QuarterRevenue Net incomeOp income FCFNet margin Op margin
2026-03-31 $0.0B $-0.1B $-0.1B $-0.1B -228.5% -332.9%
2025-12-31 $0.0B $-0.1B $-0.1B $-0.1B -227.5% -285.4%
2025-09-30 $0.0B $-0.1B $-0.1B $-0.1B -245.8% -346.2%
2025-06-30 $0.0B $-0.1B $-0.1B $-0.1B -320.7% -368.1%
2025-03-31 $0.0B $-0.1B $-0.2B $-0.1B -333.6% -482.5%
2024-12-31 $nanB $nanB $nanB $nanB nan% nan%

Tip: toggle P/E, FCF, ROE, Gross margin and more on the chart above — every overlay is free.

Compare GRAL vs peers

Line GRAL up against up to 4 peers (5 tickers total) across ~30 metrics and get one weighted 0-100 verdict — best in green, worst in red. Peers also overlay on the chart above as rebased % lines, or flip the chart to the 2×2 grid for side-by-side mini charts.

Comparing GRAL no peers yet — add up to 4 below

Add tickers to compare with GRAL

~30 metrics across Snapshot, OdysseyHQ zone, Valuation, Growth, Quality, Technicals, Sentiment, and Risk — with a weighted score and a one-line read on each.

Earnings replay · last 7 reports

How this stock actually behaves on report day: each past earnings print with the beat-or-miss and the next-day move — a track record for handicapping the next one.

DateEPS actual EPS estSurprise Next-day
2026-05-05 -1.37 -1.96 +30.1% +15.3%
2026-02-19 -2.44 -2.53 +3.6% -50.5%
2025-11-12 -2.46 -3.26 +24.7% -1.9%
2025-08-12 -3.18 -3.56 +10.8% +1.1%
2025-05-13 -3.10 -3.80 +18.5% -23.3%
2025-02-20 -2.89 -4.97 +41.9% -14.7%
2024-11-12 -3.50 -6.43 +45.5% +5.5%

Earnings markers are overlaid on the daily price chart above. Click a ▲ marker for that day's move.

Peer comparison · Healthcare

Context check: the same key numbers for the closest Healthcare names side by side, so you can tell whether this stock is the standout or just moving with its group.

Ticker ⇅ Mkt cap ⇅ P/E ⇅ Fwd P/E ⇅ P/S ⇅ EV/EBITDA ⇅ P/B ⇅ Gross M ⇅ Rev gr ⇅ EPS gr ⇅ FCF yld ⇅
GRAL $3B -7.5 20.0 -6.5 1.2 49.3% 28.1% -3.46%
LLY $1,051B 41.8 26.3 14.6 30.1 33.8 82.8% 55.5% 169.9% 0.87%
UNH $387B 32.1 19.2 0.9 17.7 4.0 19.5% 0.4% 61.5% 5.88%
JNJ $609B 29.3 19.7 6.2 18.4 7.5 68.1% 6.6% -1.0%
MRK $315B 36.0 13.2 4.8 12.1 6.9 76.7% 4.9% 4.46%
ABBV $450B 124.8 15.6 7.2 17.2 -67.6 72.0% 12.4% -46.2% 4.63%
PFE $143B 19.1 8.8 2.3 7.6 1.6 74.8% 5.4% -10.1% 8.67%
TMO $198B 29.2 19.5 4.4 21.1 3.8 40.9% 6.2% 11.3% 2.79%

Auto-seeded from sector. Click any ticker to switch.

Ownership

Who holds the stock and what they've been doing lately — big funds on the left, executives' own buys and sells on the right. Insider buying is the rarer, louder signal.

Top institutional holders

Top-10 concentration: 50.39%

HolderShares% out
Baker Bros. Advisors, LP 4,028,614 9.39%
Farallon Capital Management LLC 3,253,684 7.58%
Blackrock Inc. 2,968,536 6.92%
State Street Corporation 1,891,893 4.41%
Primecap Management Company 1,843,772 4.30%
Deep Track Capital, Lp 1,722,797 4.01%
Sessa Capital IM, L.P. 1,719,314 4.01%
Morgan Stanley 1,632,195 3.80%
Vanguard Capital Management LLC 1,527,105 3.56%
Arbiter Partners Capital Management 1,034,597 2.41%

Insider activity · 90d

6 buys / 1 sells · ratio 6.0 · Finnhub

  • Krevans Sarah BUY 42,628 @ $63.74
  • CHASE WILLIAM J BUY 42,702 @ $63.74
  • MIZELL STEVEN BUY 42,562 @ $63.74
  • SUMME GREGORY L BUY 45,245 @ $63.74
  • Partridge Andrew John SELL 163,738 @ $61.08
  • Ofman Joshua J. BUY 402,271 @ $61.13
  • Ofman Joshua J. BUY 399,117 @ $64.40

Analyst estimates

Finnhub

What Wall Street expects next: the consensus forecasts for the coming quarters. The market usually reacts to results versus these numbers, not the raw results themselves.

Low
$56.0
Mean
$70.125
High
$88.0
Analysts
8
Recommendation distribution · period 2026-07-01
4
5
6
Revision trend (2026-04-01 → 2026-07-01): net 9 → 9 0 (net = strong_buy+buy − sell−strong_sell)

SEC filings

The company's own paperwork, straight from the regulator — annual and quarterly reports, big announcements and insider trades. The primary source behind every headline.

FormFiled DescriptionAction
4 2026-07-16 FORM 4 view ·
4 2026-07-16 FORM 4 view ·
4 2026-07-16 FORM 4 view ·
4 2026-06-22 FORM 4 view ·
4 2026-06-22 FORM 4 view ·
4 2026-06-22 FORM 4 view ·
4 2026-06-22 FORM 4 view ·
8-K 2026-06-22 8-K view ·
4 2026-06-05 FORM 4 view ·
4 2026-06-03 FORM 4 view ·
8-K 2026-06-01 8-K view ·
10-Q 2026-05-07 10-Q view ·
8-K 2026-05-05 8-K view ·
DEF 14A 2026-04-28 DEF 14A view ·
4 2026-04-17 FORM 4 view ·
4 2026-04-17 FORM 4 view ·
4 2026-04-17 FORM 4 view ·
4 2026-04-09 FORM 4 view ·
4 2026-04-09 FORM 4 view ·
4 2026-04-09 FORM 4 view ·
10-K 2026-03-12 10-K view ·
4 2026-03-09 FORM 4 view ·
4 2026-03-09 FORM 4 view ·
4 2026-03-09 FORM 4 view ·
4 2026-03-03 FORM 4 view ·
4 2026-03-03 FORM 4 view ·
4 2026-03-03 FORM 4 view ·
8-K 2026-02-19 8-K view ·
4 2026-01-16 FORM 4 view ·
4 2026-01-16 FORM 4 view ·
4 2026-01-16 FORM 4 view ·
8-K 2026-01-12 8-K view ·
4 2025-12-05 FORM 4 view ·
4 2025-12-05 FORM 4 view ·
4 2025-12-05 FORM 4 view ·
4 2025-11-19 FORM 4 view ·
4 2025-11-18 Insider transaction (Form 4) view ·
8-K 2025-11-14 8-K view ·
10-Q 2025-11-13 10-Q view ·
8-K 2025-11-12 8-K view ·
8-K 2025-10-20 8-K view ·
4 2025-10-16 FORM 4 view ·
4 2025-10-16 FORM 4 view ·
4 2025-10-16 FORM 4 view ·
4 2025-10-16 FORM 4 view ·
4 2025-10-16 FORM 4 view ·
8-K 2025-10-16 8-K view ·
4 2025-10-08 FORM 4 view ·
4 2025-10-03 FORM 4 view ·
8-K 2025-09-18 8-K view ·
4 2025-08-20 FORM 4 view ·
4 2025-08-20 FORM 4 view ·
10-Q 2025-08-13 10-Q view ·
8-K 2025-08-12 8-K view ·
4 2025-07-17 FORM 4 view ·
4 2025-07-17 FORM 4 view ·
4 2025-07-17 FORM 4 view ·
4 2025-07-17 FORM 4 view ·
4 2025-07-03 FORM 4 view ·
4 2025-07-01 FORM 4 view ·

About GRAL

GRAIL, Inc., a commercial-stage healthcare company, provides multi-cancer early detection testing and services in the United States and internationally. It offers Galleri, a cancer screening test for asymptomatic individuals over 50 years of age; and a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients with clinical suspicion of cancer. The company also provides development services, including support for ongoing clinical studies, pilot testing, research, and therapy development. In addition, its precision oncology portfolio consists of n RUO-targeted methylation-based platform that enables applications for disease prognostication, risk stratification, minimal residual disease detection, and recurrence and relapse monitoring. The company was incorporated in 2015 and is headquartered in Menlo Park, California.

Options picks · GRAL

ITM + OTM ideas from the latest scan

Loading…

Congress trades · GRAL

STOCK Act disclosures

Loading…

SEC filings & insiders · GRAL

EDGAR · live

Loading…

Holders · GRAL

Institutions & insider activity

Loading…